- Home
- PRG vs VRDN Comparison
PRG vs VRDN Comparison
Compare PRG & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRG
- VRDN
- Stock Information
- Founded
- PRG 2020
- VRDN 2006
- Country
- PRG United States
- VRDN United States
- Employees
- PRG N/A
- VRDN N/A
- Industry
- PRG Diversified Commercial Services
- VRDN Medical Specialities
- Sector
- PRG Consumer Discretionary
- VRDN Health Care
- Exchange
- PRG Nasdaq
- VRDN Nasdaq
- Market Cap
- PRG 1.8B
- VRDN 1.5B
- IPO Year
- PRG N/A
- VRDN N/A
- Fundamental
- Price
- PRG $42.01
- VRDN $19.53
- Analyst Decision
- PRG Buy
- VRDN Buy
- Analyst Count
- PRG 6
- VRDN 12
- Target Price
- PRG $53.00
- VRDN $36.44
- AVG Volume (30 Days)
- PRG 379.4K
- VRDN 1.7M
- Earning Date
- PRG 02-19-2025
- VRDN 02-25-2025
- Dividend Yield
- PRG 1.11%
- VRDN N/A
- EPS Growth
- PRG 8.67
- VRDN N/A
- EPS
- PRG 3.58
- VRDN N/A
- Revenue
- PRG $2,417,577,000.00
- VRDN $302,000.00
- Revenue This Year
- PRG $2.85
- VRDN $2.55
- Revenue Next Year
- PRG $6.70
- VRDN N/A
- P/E Ratio
- PRG $12.05
- VRDN N/A
- Revenue Growth
- PRG N/A
- VRDN N/A
- 52 Week Low
- PRG $27.84
- VRDN $11.40
- 52 Week High
- PRG $50.28
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- PRG 38.37
- VRDN 47.23
- Support Level
- PRG $41.05
- VRDN $18.77
- Resistance Level
- PRG $44.86
- VRDN $19.77
- Average True Range (ATR)
- PRG 1.53
- VRDN 1.23
- MACD
- PRG -0.40
- VRDN 0.13
- Stochastic Oscillator
- PRG 24.97
- VRDN 38.85
About PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The Company has two reportable segments: (i) Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and (ii) Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the progressive leasing segment.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.